1
|
Taniguchi F, Azuma Y, Terakawa N, Harada T. Lipopolysaccharide promotes the development of murine endometriosis-like lesions via nuclear factor-kappa B pathway. Fertil Steril 2016. [DOI: 10.1016/j.fertnstert.2016.07.781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Taniguchi F, Higaki H, Izawa M, Iwabe T, Terakawa N, Harada T. Inhibitor of apoptosis protein (IAP)-2 is a novel therapeutic target for endometriosis. Fertil Steril 2012. [DOI: 10.1016/j.fertnstert.2012.07.340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Takai E, Taniguchi F, Iwabe T, Terakawa N, Harada T. The NFκB inhibitor parthenolide reduces cell proliferation and PGE2 synthesis in human endometriotic stromal cells and inhibits development of endometriosis in murine model. Fertil Steril 2012. [DOI: 10.1016/j.fertnstert.2012.07.339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Taniguchi F, Izawa M, Uegaki T, Iwabe T, Terakawa N, Harada T. TNFα is a potent mediator of regulating IAP expression in endometriotic cells. Fertil Steril 2011. [DOI: 10.1016/j.fertnstert.2011.07.534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
5
|
Taniguchi F, Izawa M, Iwabe T, Terakawa N, Harada T. Aberrant expression of IAP family in endometriotic cells may cause resistance to apoptosis. Fertil Steril 2010. [DOI: 10.1016/j.fertnstert.2010.07.779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Watanabe A, Taniguchi F, Izawa M, Suou K, Uegaki T, Takai E, Terakawa N, Harada T. The role of survivin in the resistance of endometriotic stromal cells to drug-induced apoptosis. Hum Reprod 2009; 24:3172-9. [DOI: 10.1093/humrep/dep305] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Taniguchi F, Harada T, Ikeda A, Watanabe A, Iwabe T, Terakawa N. Exploring mechanisms for regulating growth and survival of ectopic endometriotic cells using comprehensive DNA microarray analysis. Fertil Steril 2008. [DOI: 10.1016/j.fertnstert.2008.07.236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Harada T, Takenaka Y, Taniguchi F, Iwabe T, Terakawa N. Lipopolysaccharide promoted proliferation and invasion of endometriotic stromal cells via induction of cyclooxygenase-2. Fertil Steril 2008. [DOI: 10.1016/j.fertnstert.2008.07.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Shimogai R, Kigawa J, Itamochi H, Iba T, Kanamori Y, Oishi T, Shimada M, Sato S, Kawaguchi W, Sato S, Terakawa N. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. Int J Gynecol Cancer 2008; 18:499-505. [PMID: 18476949 DOI: 10.1111/j.1525-1438.2007.01055.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
We conducted study to determine whether and how the expression of the hypoxia-inducible factor 1alpha (HIF-1alpha) gene relates to outcome in patients with epithelial ovarian cancer. A total of 66 patients with epithelial ovarian cancer, who underwent primary surgery followed by platinum-based chemotherapy, were entered into this study. We confirmed the expression of HIF-1alpha and the vascular endothelial growth factor (VEGF) by immunohistochemistry. To determine the quantity of HIF-1alpha and VEGF expression, messenger RNA of each gene was measured by real-time reverse transcription-polymerase chain reaction. The cutoff values were determined by the receiver-operating characteristic curve according to survival. The protein expressions of HIF-1alpha and VEGF were strongly observed in the cancer cells. The cutoff value of HIF-1alpha and VEGF gene expression was 6.0 and 3.0, respectively. The expression of HIF-1alpha did not relate to clinical stage, but tumor with low VEGF expression was observed more frequently in stage I patients. The response rate to chemotherapy did not differ between high and low expression of both genes. The overall survival for patients with high expression of HIF-1alpha was significantly lower, but disease-free survival did not differ between high and low expression of HIF-1alpha, whereas both overall and disease-free survival for patients with high expression of VEGF were significantly lower. Multivariate analysis revealed that FIGO stage and HIF-1alpha expression were independent prognostic factors but that VEGF was not. The present study suggested that the expression level of HIF-1alpha could be an independent prognostic factor in epithelial ovarian cancer.
Collapse
Affiliation(s)
- R Shimogai
- Department of Obstetrics and Gynecology, Tottori University, School of Medicine, Nishimachi, Yonago, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kigawa J, Kawaguchi W, Itamochi H, Kanamori Y, Oishi T, Shimada M, Sato S, Sato S, Terakawa N. Effect of simultaneous inhibition of MEK and PI3K/Akt pathways on paclitaxel sensitivity in ovarian cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.16046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16046 Background: Paclitaxel (PTX) is one of the key drugs for ovarian cancer treatment. PTX activates the Raf-mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3’-kinase (PI3K) pathways that lead to cell survival pathways. The purpose of this study was to clarify whether and how the inhibitors of MEK and/or PI3K affect the sensitivity to PTX in ovarian cancer cells. Methods: We treated five ovarian cancer cell lines in combination with PTX and MEK- [PD98059 (PD)] and/or PI3K-inhibitor [LY294002 (LY)] and assessed cell viability, apoptosis, and the expression of phosphorylated (p) MEK and pAkt. The sensitivity of the cell lines to PTX was determined by 3-(4,5- dimethylthiazol-2-yl) -2,5-dyphenyltetrazolium bromide (MTT) assay. The level of protein expression was analyzed by western blot analysis. The drug-induced apoptosis was assessed by Annexin V-FITC staining. Additionally, KOC-2S was injected to intraperitoneal cavity of nude mouse. The effect of combined treatment on the survival in xenograft model was investigated. Results: The levels of pMEK and pAkt protein expression were higher in PTX resistant cell lines (KOC-2S and KFTx) than that in sensitive cell lines (KF, SHIN-3, SK-OV-3). Treatment of PTX induced MEK activation in all five ovarian cancer cell lines. The combination of PTX with either PD or LY led to additive effect on cell growth inhibition. In contrast, synergistic effect was observed in the combination of PTX with PD and LY. Furthermore, apoptotic cells were significantly increased after exposure to PTX and both inhibitors in comparison with other treatment conditions, such as PTX alone, PTX with either PD or LY. The level of pMEK induced by PTX was down-regulated by PD. Interestingly, the level of pAkt was up-regulated by the combination of PTX with PD, which was reduced by LY. Treatment with PTX, PD, and LY prolonged survival in an ovarian cancer xenograft model (p < 0.01). Conclusions: The present study suggests that simultaneous inhibition of MEK and PI3K/Akt pathways enhances the sensitivity to PTX in ovarian cancer. The combination of PTX with MEK- and PI3K-inhibitor may be a new treatment strategy for ovarian cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Kigawa
- Tottori Univ School of Medcn, Yonago Tottori, Japan
| | - W. Kawaguchi
- Tottori Univ School of Medcn, Yonago Tottori, Japan
| | - H. Itamochi
- Tottori Univ School of Medcn, Yonago Tottori, Japan
| | - Y. Kanamori
- Tottori Univ School of Medcn, Yonago Tottori, Japan
| | - T. Oishi
- Tottori Univ School of Medcn, Yonago Tottori, Japan
| | - M. Shimada
- Tottori Univ School of Medcn, Yonago Tottori, Japan
| | - S. Sato
- Tottori Univ School of Medcn, Yonago Tottori, Japan
| | - S. Sato
- Tottori Univ School of Medcn, Yonago Tottori, Japan
| | - N. Terakawa
- Tottori Univ School of Medcn, Yonago Tottori, Japan
| |
Collapse
|
11
|
Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, Numa F, Okada M, Aotani E, Terakawa N. Comparative phase II study of intraperitoneal (IP) versus intravenous (IV) carboplatin administration with IV paclitaxel in patients with bulky residual disease after primary debulking surgery for epithelial ovarian or primary peritoneal cancer: A Sankai Gynecology Study Group (SGSG) study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5584 Background: To assess the anti-tumor effect and safety of IP carboplatin (C) administration comparing with IV C administration in combination with IV infusion of paclitaxel (P). Methods: This is a non-randomized comparative phase II trial. Eligible patients were those with histologically confirmed epithelial ovarian or primary peritoneal cancer who received initial surgery and ended up with residual disease >= 2 cm. They must have reasonable hematological, hepatic, renal function before receiving chemotherapy. The patients received either of the following treatment arms; IP Arm: IV P 175 mg/m2 over 3h followed by IP C AUC6, IV Arm: IV P 175 mg/m2 over 3h followed by IV C AUC6. The treatments were scheduled to repeat 6–8 cycles. Interval debulking surgery was allowed after 3 to 5 cycle of treatment. Each participating institution had to declare, before the study was opened, which of the treatment arms the patients from the institution would be entered. Primary endpoint was a response. Secondary endpoints were toxicity and progression-free survival (PFS) and overall survival (OS). Target accrual was 30 patients in each arm. Results: Total accrual was 26 patients for IP arm and 30 patients for IV arm between 2001 and 2005. The study was closed early, because of the conflict of protocols for IP treatment. Eligible patients were 24 in IP Arm and 25 for IV arm. Median number of treatment cycle was 6 for both arms. Although the difference was not statistically significant, response rate was better in the IP Arm. Response rates were 83.3% (95%CI: 62.6%-95.3%) for IP Arm and 60.0% (95%CI: 38.7%-78.9%) for IV Arm. As of median followup of 31 months, median PFS is 25 months for IP Arm and 21 months for IV Arm,. Median OS is not reached for IP Arm, and 52 months for IV arm. Incidences of hematological and non-hematological toxicities were essentially the same on both arms. Conclusions: IP administration of C may be a better treatment strategy for epithelial ovarian and primary peritoneal cancer patients. A randomized phase III trial including bulky residual disease for comparison of IP and IV carboplatin treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Fujiwara
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - S. Nagao
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - J. Kigawa
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - J. Noma
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - N. Akamatsu
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - Y. Miyagi
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - F. Numa
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - M. Okada
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - E. Aotani
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| | - N. Terakawa
- Saitama Medical University, Iruma, Japan; Tottori University, Yonago-City, Japan; Hiroshima City Hospital, Hiroshima-City, Japan; Himeji Red Cross Hospital, Himeji-City, Japan; Ohfuku Clinic, Okayama-City, Japan; Tokuyama Central Hospital, Shunan-City, Japan; Yamaguchi Red Cross Hospital, Yamaguchi-City, Japan; The Kitasato Institute, Tokyo, Japan
| |
Collapse
|
12
|
Shimada M, Kigawa J, Terakawa N, Nishimura R, Takano T, Yaegashi N, Takehara K, Suzuki M, Yokoyama Y, Hiura M. The significance of radiotherapy for adenocarcinoma of uterine cervix. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5590 Background: We conducted the present study to determine the significance of radiotherapy for cervical adenocarcinoma. Methods: A total of 1,133 patients with cervical cancer, who underwent radiotherapy in 7 institutes between 1996 and 2005, were enrolled in this study. There were 966 squamous cell carcinoma (SCC) and 167 adenocarcinoma (AC). The mean age of patients with AC was 53.6 (range: 28–81) and 55.9 (range: 22–92) for SCC. Patients were distributed as follows: 370 in stage 1b, 116 in stage IIa, 344 in stage IIb, 16 in stage IIIa, 240 in stage IIIb, and 47 in stage IVa. All patients were identified with the medical records. Of 1,133 patients, 544 received radiotherapy as primary treatment, and 589 underwent adjuvant radiotherapy. Results: Regarding primary treatment, the 5-year survival rate for AC was 41.8% and that for SCC was 62.5% (p=0.0172). The rate of refractory or recurrence for patients with AC was significantly higher than that for SCC (53.3% vs. 33.3%, p=0.0068). Patients with AC more commonly showed recurrence inside irradiated field compared with SCC (83.3% vs. 58.2%, p=0.0240). The outcome for patients with AC was significantly worse compared with SCC in adjuvant treatment (5-year survival rate: 27.5% vs. 45.4%, p=0.0434). Recurrence for AC were significantly higher observed than that for SCC (40.0% vs. 24.7%, p=0.0008). The incidence of recurrence inside irradiated field and lymph node involvement did not differ between AC and SCC (30.1% vs. 43.8%, 46.7% vs. 44.0%). Conclusions: Cervical adenocarcinoma had poorer prognosis because of its low radiosensitivity compared with SCC. New strategy for cervical adenocarcinoma should be necessary. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Shimada
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| | - J. Kigawa
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| | - N. Terakawa
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| | - R. Nishimura
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| | - T. Takano
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| | - N. Yaegashi
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| | - K. Takehara
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| | - M. Suzuki
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| | - Y. Yokoyama
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| | - M. Hiura
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Tohoku University, Sendai, Japan; National Hospital Organization Kure Medical Center, Kure, Japan; Jichi Medical School, Utsunomiya, Japan; Hirosaki University, Hirosaki, Japan; Shikoku Cancer Center Hospital, Matsuyama, Japan
| |
Collapse
|
13
|
Oishi T, Itamochi H, Kigawa J, Kanamori Y, Shimada M, Takahashi M, Shimogai R, Kawaguchi W, Sato S, Terakawa N. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2007; 17:1040-6. [PMID: 17433067 DOI: 10.1111/j.1525-1438.2007.00916.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Our previous findings suggested that lower cell proliferation of clear cell carcinoma (CCC) of the ovary may contribute to its resistance to chemotherapy. We conducted the present study to find the gene that regulates cell proliferation of CCC and to elucidate whether it contributes to cisplatin (CDDP) resistance. Complementary DNA microarray analysis revealed that the gene expression level of galectin-3 of CCC cell lines (KK, RMG-I, HAC-2) was over threefold higher than that of ovarian serous adenocarcinoma (SAC) cell lines (HRA, KF). S-phase fraction increased after knocking down galectin-3 using small interfering RNA in RMG-I, KK, and HAC-2 cells. The protein expression of p27 decreased after knocking down galectin-3. CDDP-induced apoptosis was increased after knocking down galectin-3, and this cytotoxic effect was canceled by roscovitine. Immunohistochemical staining showed that galectin-3 expression in tumors of 20 CCC was significantly more frequent than that of 20 SAC (70.0% vs 15.0%, P = 0.0004). The present study showed that the expression of galectin-3 in CCC might contribute to its lower cell proliferation and lead to CDDP resistance.
Collapse
Affiliation(s)
- T Oishi
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shimogai R, Kawaguchi W, Sato S, Terakawa N. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17:76-82. [PMID: 17291235 DOI: 10.1111/j.1525-1438.2006.00752.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
We conducted the present study to investigate whether and how chemosensitivity can be determined by means of genetic diagnosis using drug-resistance genes in patients with epithelial ovarian cancer. A total of 75 patients who had epithelial ovarian cancer with measurable lesions were entered into this study. Thirty-three patients received first-line chemotherapy, consisting of paclitaxel and carboplatin (TJ). Forty-two patients received second-line chemotherapy, 22 received EP therapy consisting of etoposide and cisplatin (CDDP), and 20 received irinotecan (CPT-11) and CDDP (CPT-11/CDDP) therapy. Tumor samples were obtained before chemotherapy. MessengerRNA expressions of the multidrug-resistance (MDR)-1 gene, MDR-associated protein-1 (MRP-1), topoisomerase (topo) I, and topo IIalpha were measured by real-time reverse transcription-polymerase chain reaction. The cutoff values of each gene were determined by the receiver operating characteristic curve. MDR-1 expression was significantly higher in patients who did not respond to TJ therapy. The expression of topo IIalpha was significantly higher in patients who did respond to EP therapy. The expression of topo I was significantly higher in patients who did respond to CPT-11/CDDP. MRP-1 expression did not differ between responders and nonresponders in all regimens. The cutoff value was 80 for MDR-1, 90 for topo IIalpha, and 200 for topo I. Next, to evaluate genetic diagnosis, 31 patients were newly added. The accuracy of this genetic diagnosis for chemosensitivity was 85.7% for TJ, 77.8% for EP, and 100.0% for CPT-11/CDDP therapy. The present study suggests that genetic diagnosis may be useful to determine chemosensitivity in patients with epithelial ovarian cancer.
Collapse
MESH Headings
- Adult
- Aged
- Antigens, Neoplasm/biosynthesis
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/metabolism
- Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Camptothecin/administration & dosage
- Camptothecin/analogs & derivatives
- Carboplatin/administration & dosage
- Cisplatin/administration & dosage
- DNA Topoisomerases, Type I/biosynthesis
- DNA Topoisomerases, Type I/genetics
- DNA Topoisomerases, Type I/metabolism
- DNA Topoisomerases, Type II/biosynthesis
- DNA Topoisomerases, Type II/genetics
- DNA Topoisomerases, Type II/metabolism
- DNA-Binding Proteins/biosynthesis
- DNA-Binding Proteins/genetics
- DNA-Binding Proteins/metabolism
- Drug Resistance, Multiple/genetics
- Drug Resistance, Neoplasm/genetics
- Epithelial Cells/pathology
- Female
- Genes, MDR
- Humans
- Irinotecan
- Middle Aged
- Multidrug Resistance-Associated Proteins/biosynthesis
- Multidrug Resistance-Associated Proteins/genetics
- Multidrug Resistance-Associated Proteins/metabolism
- Ovarian Neoplasms/drug therapy
- Ovarian Neoplasms/genetics
- Ovarian Neoplasms/metabolism
- Ovarian Neoplasms/pathology
- Paclitaxel/administration & dosage
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
Collapse
Affiliation(s)
- J Naniwa
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishimachi, Yonago 683-8504, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Shimada M, Kigawa J, Terakawa N, Yoshizaki A, Shoji T, Suzuki M, Hatae M, Tsuda H, Ohwada M, Sugiyama T. Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer. Int J Gynecol Cancer 2007; 17:210-4. [PMID: 17291255 DOI: 10.1111/j.1525-1438.2007.00801.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Doxorubicin, platinum compounds, and taxanes represent the chemotherapeutic agents with the greatest activity in endometrial cancer. We conducted an optimal-dose determination of combination chemotherapy consisting of paclitaxel (TXL), doxorubicin, and carboplatin (CBDCA) (TAC) in patients with endometrial cancer. Patients with epithelial endometrial cancer requiring adjuvant therapy were enrolled between June 2003 and March 2005. No patients had received prior radiotherapy, and only two patients had previously undergone chemotherapy. Doxorubicin was infused on day 1, and TXL followed by CBDCA was administered on day 2. The starting dose was doxorubicin 35 mg/m2, TXL 120 mg/m2, and CBDCA area under the curve (AUC). The dose of each agent was gradually escalated. Patients were scheduled to receive at least four cycles of therapy. If patients experienced grade 4 neutropenia or neutropenic fever with grade 3 neutropenia, they were permitted to be administered granulocyte colony–stimulating factor after the second course. Twenty-seven patients were enrolled. Although four patients out of 27 experienced dose-limiting toxicities, a maximum tolerated dose was not established at the final dose level. Five patients (three for recurrent and two for advanced) had measurable lesions. There were four responders (three for partial response and one for complete response) in our series. The recommended dose of TAC therapy for endometrial cancer was doxorubicin 45 mg/m2 for day 1, TXL 150 mg/m2 and CBDCA AUC 5 for day 2.
Collapse
Affiliation(s)
- M Shimada
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Kigawa J, Shimada M, Minagawa Y, Kanamori Y, Itamochi H, Kitada F, Okada M, Terakawa N. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.15055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15055 Background: The carboplatin-paclitaxel combination therapy is a gold standard regimen for patients with ovarian cancer. However, combination chemotherapy continues to produce significant neurotoxicity, a serious adverse effect. We conducted the present study to determine the feasibility of docetaxel-cisplatin combination therapy compared with docetaxel-carboplatin combination therapy as first-line chemotherapy for patients with ovarian cancer. Methods: Fifty patients with International Federation of Gynecology and Obstetrics stage Ic-IV ovarian cancer who underwent primary surgery were randomly assigned to receive treatment with docetaxel-cisplatin (n = 23) or docetaxel-carboplatin (n = 27). Docetaxel 70 mg/m2 and cisplatin 60 mg/m2 or carboplatin to an area under the curve = of 5 were administered consecutively on Day 1 of a 3-week cycle, for 3 cycles in patients with stage Ic-II cancer and for over 5 cycles in patients with stage III-IV cancer. Patients were evaluated for treatment-related toxicity in each cycle using the National Cancer Institute Common Toxicity Criteria version 2.0. Results: Five patients (2 in the docetaxel-cisplatin arm and 3 in the docetaxel-carboplatin arm) discontinued the treatment at the end of the second course of chemotherapy because of apparent disease progression; however, no patients came off the protocol therapy because of treatment-related toxicity. Overall, 103 cycles of docetaxel-cisplatin treatment and 130 cycles of docetaxel-carboplatin treatment were delivered. The major toxicity was neutropenia in both regimens. The total incidence of grades 3 and 4 neutropenia was 83% (19/23) in the docetaxel-cisplatin arm and 96% (26/27) in the docetaxel-carboplatin arm. The incidence of grade 4 neutropenia was significantly lower in the docetaxel-cisplatin arm [39% (9/23) vs. 74% (20/27)]. Conclusions: Docetaxel-cisplatin combination therapy may be feasible as first-line chemotherapy for patients with ovarian cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Kigawa
- Tottori University, Yonago, Japan; Tottori Prefectural Central Hospital, Tottori, Japan; Osaka Saiseikai Suita Hospital, Osaka, Japan; Yamaguchi Red Cross Hospital, Yamaguchi, Japan
| | - M. Shimada
- Tottori University, Yonago, Japan; Tottori Prefectural Central Hospital, Tottori, Japan; Osaka Saiseikai Suita Hospital, Osaka, Japan; Yamaguchi Red Cross Hospital, Yamaguchi, Japan
| | - Y. Minagawa
- Tottori University, Yonago, Japan; Tottori Prefectural Central Hospital, Tottori, Japan; Osaka Saiseikai Suita Hospital, Osaka, Japan; Yamaguchi Red Cross Hospital, Yamaguchi, Japan
| | - Y. Kanamori
- Tottori University, Yonago, Japan; Tottori Prefectural Central Hospital, Tottori, Japan; Osaka Saiseikai Suita Hospital, Osaka, Japan; Yamaguchi Red Cross Hospital, Yamaguchi, Japan
| | - H. Itamochi
- Tottori University, Yonago, Japan; Tottori Prefectural Central Hospital, Tottori, Japan; Osaka Saiseikai Suita Hospital, Osaka, Japan; Yamaguchi Red Cross Hospital, Yamaguchi, Japan
| | - F. Kitada
- Tottori University, Yonago, Japan; Tottori Prefectural Central Hospital, Tottori, Japan; Osaka Saiseikai Suita Hospital, Osaka, Japan; Yamaguchi Red Cross Hospital, Yamaguchi, Japan
| | - M. Okada
- Tottori University, Yonago, Japan; Tottori Prefectural Central Hospital, Tottori, Japan; Osaka Saiseikai Suita Hospital, Osaka, Japan; Yamaguchi Red Cross Hospital, Yamaguchi, Japan
| | - N. Terakawa
- Tottori University, Yonago, Japan; Tottori Prefectural Central Hospital, Tottori, Japan; Osaka Saiseikai Suita Hospital, Osaka, Japan; Yamaguchi Red Cross Hospital, Yamaguchi, Japan
| |
Collapse
|
17
|
Satoi S, Yanagimoto H, Takai S, Toyokawa H, Takahashi K, Terakawa N, Yamamoto T, Kamiyama Y. Circulating dendritic cell as a new prognostic factor in pancreatic cancer patients. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4095 Background: Pancreatic cancer is a cancer with very poor prognosis that might be associated with impaired immune defense. Dendritic cells (DC) are important for immune surveillance and play a central role in protection against infection and malignancy. A defective host antitumor immune response may allow tumor cells to escape from the host immune system. The aim of this study is to determine whether circulating DC could be one of new immunological markers that may predict the prognosis of the pancreatic cancer. Methods: We evaluated pretreatment circulating myeloid-lineage DC (C-DC1) rate in the peripheral blood mononuclear cell and various clinical parameters to determine their prognostic value in 104 pancreatic cancer patients (41 resected and 63 unresected patients) seen at our institution. Results: In unresected patients, univariate analysis demonstrated two risk factors for prognosis of albmin < 3.8g/dl (p = 0.0468), and C-DC1 < 0.27% (p = 0.0006), when all patients were divided by the median value of C-DC1 rate. Consequently, multivariate analysis demonstrated that only C-DC1 was a predominant independent predictor of survival (Hazard ratio; 9.330, 95% Confidential interval; 2.595–33.549, p = 0.0006). In resected patients, C-DC1 in patients with advanced disease (Stages 2b-4, n=28) was significantly lower than that in patients with lower staged cancer (Stage 1–2a, n = 13: 0.43 ± 0.67%, Stage 2b-4: 0.24 ± 0.30%, p < 0.05). The overall survival rates in patients with C-DC1 ≥ 0.27% were significantly longer than those in patients with C-DC1 < 0.27 (C-DC1 ≥ 0.27%, n = 20, 1/3 year survival: 100%/64%. C-DC1 < 0.27, n = 21, 1/3 year survival: 68%/26%. P < 0.05). Conclusions: The C-DC1 less than 0.27% could be one of prognostic factors in patients with pancreatic cancer, and such patients could be targets for the future therapeutic trials. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Satoi
- Kansai Medical University Hospital, Shinmachi, Hirakata, Osaka, Japan
| | - H. Yanagimoto
- Kansai Medical University Hospital, Shinmachi, Hirakata, Osaka, Japan
| | - S. Takai
- Kansai Medical University Hospital, Shinmachi, Hirakata, Osaka, Japan
| | - H. Toyokawa
- Kansai Medical University Hospital, Shinmachi, Hirakata, Osaka, Japan
| | - K. Takahashi
- Kansai Medical University Hospital, Shinmachi, Hirakata, Osaka, Japan
| | - N. Terakawa
- Kansai Medical University Hospital, Shinmachi, Hirakata, Osaka, Japan
| | - T. Yamamoto
- Kansai Medical University Hospital, Shinmachi, Hirakata, Osaka, Japan
| | - Y. Kamiyama
- Kansai Medical University Hospital, Shinmachi, Hirakata, Osaka, Japan
| |
Collapse
|
18
|
Itamochi H, Yamasaki F, Sudo T, Takahashi T, Bartholomeusz C, Das S, Terakawa N, Ueno NT. Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther 2005; 13:451-9. [PMID: 16294215 DOI: 10.1038/sj.cgt.7700920] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Radiation-induced apoptosis is thought to underlie the toxicity of radiation to normal tissues as well as to cancer cells. We hypothesized that specific ectopic overexpression of the antiapoptotic molecule Bcl-2 in normal cells would inhibit radiation-induced apoptosis and thereby reduce radiation-induced toxicity in normal cells. To express Bcl-2 specifically in normal cells (which have wild-type (wt) p53) but not in cancer cells (which often have mutated p53), we constructed a Bcl-2 expression plasmid (PG13-Bcl-2) with a minimal promoter regulated by multiple wt p53 DNA-binding sites and found that the presence of wt p53 protein strongly upregulated Bcl-2 expression through this plasmid. Transfection of NIH 3T3 fibroblasts, which express wt p53, with PG13-Bcl-2 increased cell survival and reduced apoptosis; however, transfection of MDA-MB-231 breast cancer cells, which have mutated p53, did not affect survival and apoptosis of those cells. These results indicate that irradiation of normal cells rapidly upregulates the expression of wt p53, which binds to the p53 binding sequence of the PG13-Bcl-2 plasmid and increases the transcriptional activity of Bcl-2. Ectopic expression of Bcl-2 reduced radiation-induced apoptosis only in normal cells (not in cancer cells). Bcl-2 expression was detected in the lung from mice injected via a tail vein with LPD-PG13-Bcl-2 or LPD-CMV-Bcl-2, but did not in the lung from mice treated with DOTAP or LPD-PG13-mock. This novel approach to inhibiting radiation-induced apoptosis in normal cells may allow such cells to be protected from radiation-induced toxicity. Further preclinical in vivo studies are needed.
Collapse
Affiliation(s)
- H Itamochi
- Breast Cancer Translational Research Laboratory, Houston, TX, USA
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Shimada M, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Minagawa Y, Ishihara K, Takeuchi Y, Okada M, Terakawa N. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging. Int J Gynecol Cancer 2005; 15:601-5. [PMID: 16014112 DOI: 10.1111/j.1525-1438.2005.00115.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
We conducted the present study to determine the outcome of patients with early ovarian cancer who underwent three courses of adjuvant chemotherapy after complete surgical staging. One hundred consecutive patients with stage I-II epithelial ovarian cancer who had undergone complete surgical staging and received three courses of platinum-based chemotherapy were entered in this study. Twenty-one patients were low risk, defined as stage IA-B, grade 1 and histologic types except for clear cell adenocarcinoma, and remaining 79 were high risk. All patients with stage IA or IB, whatever histologic type and histopathologic grade, were alive without disease. The 5-year survival rate was 89.4% for patients with stage IC and 76.2% for those with stage II. The 5-year survival rate for low- and high-risk patients was 100% and 89.4%, respectively. The survival rate for grade 1 was significantly better than that for grade 2 or 3. Multivariate analysis revealed that histologic grade was an independent prognostic factor in stage IC-II ovarian cancer. The outcome of patients with early ovarian cancer undergoing three courses of chemotherapy after complete surgical staging was favorable even in high-risk patients.
Collapse
Affiliation(s)
- M Shimada
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Shimada M, Kigawa J, Nishimura R, Suzuki M, Kita T, Sugiyama T, Hiura M, Kaku T, Tsuda H, Terakawa N. Clinical characteristics of mucinous adenocarcinoma of the ovary. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Shimada
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| | - J. Kigawa
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| | - R. Nishimura
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| | - M. Suzuki
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| | - T. Kita
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| | - T. Sugiyama
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| | - M. Hiura
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| | - T. Kaku
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| | - H. Tsuda
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| | - N. Terakawa
- Tottori Univ, Yonago, Japan; Hyogo Medcl Ctr for Adults, Akashi, Japan; Jichi Medcl Sch, Utsunomiya, Japan; National Defense Medcl Coll, Tokorozawa, Japan; Iwate Medcl Univ Sch of Medicine, Iwate, Japan; Shikoku Cancer Ctr Hosp, Matsuyama, Japan; Kyushu Univ, Hukuoka, Japan; Osaka City Gen Hosp, Osaka, Japan
| |
Collapse
|
21
|
Shimada M, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Minagawa Y, Ishihara K, Takeuchi Y, Okada M, Terakawa N. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging. Int J Gynecol Cancer 2005. [DOI: 10.1136/ijgc-00009577-200507000-00004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
We conducted the present study to determine the outcome of patients with early ovarian cancer who underwent three courses of adjuvant chemotherapy after complete surgical staging. One hundred consecutive patients with stage I–II epithelial ovarian cancer who had undergone complete surgical staging and received three courses of platinum-based chemotherapy were entered in this study. Twenty-one patients were low risk, defined as stage IA–B, grade 1 and histologic types except for clear cell adenocarcinoma, and remaining 79 were high risk. All patients with stage IA or IB, whatever histologic type and histopathologic grade, were alive without disease. The 5-year survival rate was 89.4% for patients with stage IC and 76.2% for those with stage II. The 5-year survival rate for low- and high-risk patients was 100% and 89.4%, respectively. The survival rate for grade 1 was significantly better than that for grade 2 or 3. Multivariate analysis revealed that histologic grade was an independent prognostic factor in stage IC–II ovarian cancer. The outcome of patients with early ovarian cancer undergoing three courses of chemotherapy after complete surgical staging was favorable even in high-risk patients
Collapse
|
22
|
Osuga Y, Hayashi K, Kobayashi Y, Toyokawa S, Momoeda M, Koga K, Yoshino O, Tsutsumi O, Hoshiai H, Terakawa N, Taketani Y. Dysmenorrhea in Japanese women. Int J Gynaecol Obstet 2005; 88:82-3. [PMID: 15617718 DOI: 10.1016/j.ijgo.2004.09.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2004] [Revised: 09/08/2004] [Accepted: 09/09/2004] [Indexed: 10/26/2022]
Affiliation(s)
- Y Osuga
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Harada T, Kaponis A, Iwabe T, Taniguchi F, Makrydimas G, Sofikitis N, Paschopoulos M, Paraskevaidis E, Terakawa N. Apoptosis in human endometrium and endometriosis. Hum Reprod Update 2004; 10:29-38. [PMID: 15005462 DOI: 10.1093/humupd/dmh007] [Citation(s) in RCA: 157] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Apoptosis plays a critical role in maintaining tissue homeostasis and represents a normal function to eliminate excess or dysfunctional cells. Accumulated evidence suggests that apoptosis helps to maintain cellular homeostasis during the menstrual cycle by eliminating senescent cells from the functional layer of the uterine endometrium during the late secretory and menstrual phase of the cycle. The BCL-2 family and Fas/FasL system have been extensively studied in human endometrium and endometriotic tissues. Eutopic endometrium from women with endometriosis reportedly has some fundamental differences compared with normal endometrium of women without endometriosis. The differences could contribute to the survival of regurgitating endometrial cells into the peritoneal cavity and the development of endometriosis. One mechanism that recently gained a lot of interest is the finding that apoptosis appeared in eutopic and ectopic endometrium of patients with endometriosis. This study is a current review of the literature focused on the physiological role of apoptosis in normal endometrium and the alterations in regulation of apoptosis in eutopic and ectopic endometrium from women with endometriosis. Similarities in characteristics of endometriosis at a molecular level with gynaecological tumours are also discussed. Finally, the role of apoptosis in the treatment of endometriosis is reviewed to link the basic research findings into clinical applications.
Collapse
Affiliation(s)
- T Harada
- Department of Obstetrics and Gynaecology, Tottori University School of Medicine, 36-1 Nishimachi, 683-8504, Yonago, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Iwabe T, Harada T, Iba Y, Horie S, Deura I, Terakawa N. Lipopolysaccharide promoted proliferation of endometriotic stromal cells via induction of tumor necrosis factor a and interleukin-8 expression. Fertil Steril 2004. [DOI: 10.1016/j.fertnstert.2004.07.419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Deura I, Harada T, Taniguchi F, Iwabe T, Izawa M, Terakawa N. Interleukin-6 reduced estrogen production in a human granulosa tumor cells: Its implication in endometriosis-associated infertility. Fertil Steril 2004. [DOI: 10.1016/j.fertnstert.2004.07.420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Horie S, Harada T, Iba Y, Taniguchi F, Iwabe T, Terakawa N. The effects of dienogest, danazol and progesterone on the expression of IL-8 in endometriotic stromal cells. Fertil Steril 2004. [DOI: 10.1016/j.fertnstert.2004.07.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I. Development of a mathematical model of intraperitoneal/intravenous infusion of carboplatin. A Sankai Gynecology Study Group study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Y. Miyagi
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - K. Fujiwara
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - J. Kigawa
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - H. Itamochi
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - S. Nagao
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - E. Aotani
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - N. Terakawa
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| | - I. Kohno
- Okayama Red Cross General Hospital, Okayama-city, Japan; Kawasaki Medical School, Kurashiki-City, Japan; Tottori University, Yonago-City, Japan; Kawasaki University of Medical Welfare, Kurashiki-City, Japan
| |
Collapse
|
28
|
Shimada M, Kigawa J, Yamaguchi S, Nishimura R, Nakanishi T, Kuzuya K, Suzuki M, Kita T, Kikuchi Y, Terakawa N. Ovarian metastases in stage Ib to IIb carcinoma of the uterine cervix. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Shimada
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| | - J. Kigawa
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| | - S. Yamaguchi
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| | - R. Nishimura
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| | - T. Nakanishi
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| | - K. Kuzuya
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| | - M. Suzuki
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| | - T. Kita
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| | - Y. Kikuchi
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| | - N. Terakawa
- Tottori University, Yonago, Tottori, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Jichi Medical School, Utsunomiya, Japan; National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
29
|
Yanagimoto H, Takai S, Satoi S, Toyokawa H, Takahashi K, Terakawa N, Tanaka K, Kwon AH, Kamiyama Y. Circulating dendritic cells as a prognostic factor in patients with pancreatic cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - S. Takai
- Kansai Medical University, Moriguchi, Japan
| | - S. Satoi
- Kansai Medical University, Moriguchi, Japan
| | | | | | | | - K. Tanaka
- Kansai Medical University, Moriguchi, Japan
| | - A.-H. Kwon
- Kansai Medical University, Moriguchi, Japan
| | | |
Collapse
|
30
|
Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003; 10:203-8. [PMID: 12790783 DOI: 10.1677/erc.0.0100203] [Citation(s) in RCA: 115] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
To clarify whether and how PTEN and the phosphatidylinositol 3-kinase/Akt pathway relates to endometrial cancer we examined the expression of these pathway-related proteins in patients with endometrial cancer. Of 103 endometrial cancers, 37 (36%) showed negative immunohistochemical staining for PTEN. Western blotting revealed that the level of phosphorylated Akt expression in PTEN-negative cases was significantly higher compared with that in positive cases. We found a significant inverse correlation between PTEN and phosphorylated Akt. The present study indicates the phosphorylation of Akt accompanied by the loss of PTEN in clinical specimens of endometrial cancers. In order to investigate the relationship between PTEN expression and prognosis in endometrial cancer, 98 patients with advanced endometrial cancer were newly enrolled. The survival rate for PTEN-positive patients was significantly higher than that for PTEN-negative or -heterogeneous staining patients. Of the 98 patients, 25 underwent radiation therapy, 62 received chemotherapy after surgery, and the remaining 11 did not have any postoperative treatment. When patients underwent chemotherapy, the survival rate for PTEN-positive cases was clearly higher than that for PTEN-negative or -heterogeneous cases (62.4 vs 11.8%). Subsequent multivariate analysis revealed that PTEN staining was an independent prognostic factor for patients undergoing chemotherapy. The current study demonstrates that PTEN-positive staining is a significant prognostic indicator of favorable survival for patients with advanced endometrial cancer who undergo postoperative chemotherapy.
Collapse
Affiliation(s)
- N Terakawa
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishimachi, Yonago 683-8504, Japan
| | | | | |
Collapse
|
31
|
Sultana H, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Sato S, Kamazawa S, Ohwada M, Suzuki M, Terakawa N. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol 2003; 14:214-9. [PMID: 12562647 DOI: 10.1093/annonc/mdg071] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
OBJECTIVES To determine whether and how apoptosis through the p53-Bax pathway affects sensitivity to chemotherapy in cervical cancer. MATERIALS AND METHODS Thirty patients with cervical squamous cell carcinoma, who had human papilloma virus (HPV) and underwent neoadjuvant chemotherapy, were entered in the present study. Tumor specimens were obtained before and after chemotherapy. HPV was detected by polymerase chain reaction. The expression of Ki-67, p53, Bax and Bcl-2 proteins was determined by immunohistochemical staining. Apoptotic cells were identified by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick-end labeling method. RESULTS Of 30 patients, 18 responded to chemotherapy and 12 did not. The apoptotic index in tumors of responders was significantly higher than in non-responders after chemotherapy. The Ki-67 labeling index (LI) in responders was significantly higher than in non-responders before chemotherapy. Patients with tumors >33% of the LI, which was determined by a receiver operating characteristic curve, had a better survival rate. The incidence of p53 protein expression did not differ between responders and non-responders. After chemotherapy, the expression of Bax protein in responders was more frequent and Bcl-2 protein expression was less frequent than in non-responders. CONCLUSIONS Chemosensitivity in cervical cancer may be associated with apoptosis via the p53-Bax pathway.
Collapse
Affiliation(s)
- H Sultana
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Fujiwara K, Kigawa J, Hasegawa K, Nishimura R, Umezaki N, Ando M, Itamochi H, Yamaguchi S, Oda T, Terakawa N, Kohshima I, Kohno I. Effect of simple omentoplasty and omentopexy in the prevention of complications after pelvic lymphadenectomy. Int J Gynecol Cancer 2003. [DOI: 10.1136/ijgc-00009577-200301000-00011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
This multicenter collaborative study prospectively evaluated the effect of omentoplasty and omentopexy on the prevention of complications after pelvic lymphadenectomy. Sixty-four consecutive patients (42 cervical and 22 endometrial cancer) were enrolled and examined periodically for 12 months. All patients underwent simple, semiradical, or Okabayashi's radical hysterectomy and complete pelvic lymphadenectomy. The infracolic omentum was longitudinally divided in half and omentoplasty was performed so that bilateral omental flaps would reach the pelvic floor. The omental flaps were inserted into the retroperitoneal space and the edges of the flaps were sutured to the psoas muscle. The omental flap was then covered by the peritoneum. Incidence of lymphocele, lymphedema, and severe complications associated with lymphocele, such as infection or urinary stenosis, was evaluated at intervals for at least one year after surgery.Among the 64 patients, 12 patients received pelvic radiation because of occult lymph node metastasis. Planned omentoplasty was not possible in one patient because her omentum was too small; therefore, only unilateral omentopexy was performed. Asymptomatic lymphoceles only were detected by ultrasonogram in 12 patients (18.8%). Three patients (4.7%) had a symptomatic but pressure-only lymphocele. Hydronephrosis and bladder compression probably due to lymphocele were observed in one patient, respectively (3.1%), but resolved within 6 months. Lymphedema was observed in seven patients (10.9%) and persisted for more than 6 months in two patients (3.1%). We conclude that this simple technique of omentoplasty and omentopexy appeared to be effective in reducing the incidence of complications after pelvic lymphadenectomy.
Collapse
|
33
|
Fujiwara K, Kigawa J, Hasegawa K, Nishimura R, Umezaki N, Ando M, Itamochi H, Yamaguchi S, Oda T, Terakawa N, Kohshima I, Kohno I. Effect of simple omentoplasty and omentopexy in the prevention of complications after pelvic lymphadenectomy. Int J Gynecol Cancer 2003; 13:61-6. [PMID: 12631222 DOI: 10.1046/j.1525-1438.2003.13029.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This multicenter collaborative study prospectively evaluated the effect of omentoplasty and omentopexy on the prevention of complications after pelvic lymphadenectomy. Sixty-four consecutive patients (42 cervical and 22 endometrial cancer) were enrolled and examined periodically for 12 months. All patients underwent simple, semiradical, or Okabayashi's radical hysterectomy and complete pelvic lymphadenectomy. The infracolic omentum was longitudinally divided in half and omentoplasty was performed so that bilateral omental flaps would reach the pelvic floor. The omental flaps were inserted into the retroperitoneal space and the edges of the flaps were sutured to the psoas muscle. The omental flap was then covered by the peritoneum. Incidence of lymphocele, lymphedema, and severe complications associated with lymphocele, such as infection or urinary stenosis, was evaluated at intervals for at least one year after surgery. Among the 64 patients, 12 patients received pelvic radiation because of occult lymph node metastasis. Planned omentoplasty was not possible in one patient because her omentum was too small; therefore, only unilateral omentopexy was performed. Asymptomatic lymphoceles only were detected by ultrasonogram in 12 patients (18.8%). Three patients (4.7%) had a symptomatic but pressure-only lymphocele. Hydronephrosis and bladder compression probably due to lymphocele were observed in one patient, respectively (3.1%), but resolved within 6 months. Lymphedema was observed in seven patients (10.9%) and persisted for more than 6 months in two patients (3.1%). We conclude that this simple technique of omentoplasty and omentopexy appeared to be effective in reducing the incidence of complications after pelvic lymphadenectomy.
Collapse
Affiliation(s)
- K Fujiwara
- Department of Obstetrics and Gynecology, Kawasaki Medical School, Kurashiki-City, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, Terakawa N. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001; 14:165-71. [PMID: 11774736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Recent studies suggest that drug induced apoptosis relates to the sensitivity. p53 gene, which has a pivotal role in inducing apoptosis, frequently mutates in ovarian cancer. Therefore, p53 gene status and chemosensitivity in epithelial ovarian cancer is discussed. Nonresponders to chemotherapy had mutations of the p53 gene more frequently (83% for nonresponders vs. 16% for responders) in patients with epithelial ovarian cancer undergoing platinum-base chemotherapy. Apoptotic index was significantly greater in tumors with wild-type p53 gene than those without the gene. p53 gene transduction markedly enhanced the sensitivity to cisplatin (CDDP) and CDDP-induced apoptosis, but did not affect the sensitivity to paclitaxel (PTX) nor PTX-induced apoptosis in ovarian cancer cells without p53 gene. The combination treatment with a recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) and CDDP significantly suppressed tumor growth of ovarian cancer cells with and without p53 gene, compared with a single treatment of either AxCAp53 or CDDP in ovarian cancer xenograft. Apoptotic index was significantly higher and proliferating cell nuclear antigen labeling index was relatively lower in an ovarian cancer xenograft without p53 gene receiving combination treatment, compared with a single treatment of either CDDP or AxCAp53, suggesting that the transduction of p53 gene induces apoptosis, but does not enhance the DNA repair system. A significant survival advantage was observed in the combination treatment compared with other treatments in carcinoma peritonitis models. In conclusion, p53 gene status contributes the sensitivity to CDDP in ovarian cancer. Additionally, combination treatment of p53 gene transduction and CDDP may be an effective therapeutic modality for ovarian cancer without wild-type p53 gene.
Collapse
Affiliation(s)
- J Kigawa
- Department of Obstetrics and Gynecology, Tottori University, School of Medicine
| | | | | | | | | | | | | |
Collapse
|
35
|
Minagawa Y, Kigawa J, Itamochi H, Terakawa N. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer. Hum Cell 2001; 14:237-43. [PMID: 11774743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
We discussed the role of DNA topoisomerase I (topo I) inhibitor, which is now widely used in clinical practice, in cisplatin-resistant ovarian cancer. Our study showed the synergistic actions between cisplatin and 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of 7-ethyl-10-[4-(1-pyperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11), in two cisplatin-resistant cancer cell lines, HeLa/CDDP and KFr cells, but not in each parent cell line, HeLa and KF cells. Furthermore, HeLa/CDDP cells had a collateral sensitivity to SN-38. The levels of topo I protein in the cisplatin-resistant cells did not differ from those of their parent cell lines and were unaffected by exposure to cisplatin. In contrast, topo I enzymatic activity was 2-4 fold higher in the cisplatin-resistant cell lines compared with their respective parent cell lines. A significant correlation between the sensitivity for SN-38 and topo I activity human clear cell carcinoma cell lines, which are known as intrinsically ciasplatin-resistant cancer, was observed. Next, we examined the relationship between topo I activity and sensitivity to second-line chemotherapy consisting of cisplatin and CPT-11. A total of 30 patients with ovarian cancer who had initially undergone chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide (CAP) and exhibited measurable lesions were entered in the study. Tumor samples were obtained in the period between the initial and the second-line chemotherapy. Of those 30 patients, 18 responded to second-line chemotherapy and 12 did not. Topo I activity in tumor samples of responder was significantly greater than that of in nonresponders. In 8 cases whose samples could be obtained before and after CAP, topo I activity significantly increased after CAP therapy. Consequently, the combination therapy with cisplatin and CPT-11 may be effective for patients with cisplatin-resistant ovarian cancer. In addition, topo I enzymatic activity may be a predictor of the sensitivity for topo I inhibitor.
Collapse
Affiliation(s)
- Y Minagawa
- Department of Obstetrics and Gynecology, Tottori Prefectural Central Hospital.
| | | | | | | |
Collapse
|
36
|
Ohata Y, Harada T, Fujii A, Yoshida S, Iwabe T, Terakawa N. Menstrual cycle-specific inhibition of endometrial stromal cell proliferation by oncostatin M. Mol Hum Reprod 2001; 7:665-70. [PMID: 11420390 DOI: 10.1093/molehr/7.7.665] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
We have investigated the possible roles of oncostatin M (OSM), which is a member of the interleukin-6 family of cytokines, in endometrial and endometriotic stromal cell growth. Endometrial and endometriotic stromal cells were collected from the uterus or ovarian chocolate cysts. We observed the expression of mRNA transcripts for OSM, OSM receptor subunit beta, leukaemia inhibitory factor receptor subunit (LIFR), and glycoprotein 130 in endometrial and endometriotic stromal cells. We also examined the effects of OSM (0-50 ng/ml) and LIF (0-10 ng/ml) on endometrial and endometriotic stromal cell proliferation and evaluated the effects of OSM on endometrial stromal cell differentiation. The presence of 10-50 ng/ml OSM significantly suppressed endometrial stromal cell growth in secretory phase tissue but not in proliferative phase tissue. In contrast, stromal cells in endometriotic tissues were resistant to the inhibitory effects of OSM. Addition of LIF did not influence the growth of endometrial stromal cells. We also showed that 10 ng/ml OSM stimulated markers of differentiation causing increased prolactin secretion and cyclooxygenase-2 gene expression in endometrial stromal cells from the secretory phase. These results suggest that OSM may play a pivotal role in regulating the growth and differentiation of endometrial cells. Endometriotic cells may behave differently from normal endometrial cells in terms of the inhibitory response to OSM.
Collapse
Affiliation(s)
- Y Ohata
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago 683-8504, Japan.
| | | | | | | | | | | |
Collapse
|
37
|
Abstract
OBJECTIVE To review the literature on the role of cytokines in the pathogenesis of endometriosis and endometriosis-associated infertility. DESIGN Pertinent studies were identified by a computer search of MEDLINE. References of selected articles were hand-searched for additional citations. RESULT(S) Recent studies suggest that the peritoneal fluid of women with endometriosis contains an increased number of activated macrophages that secrete various local products, such as growth factors and cytokines. Levels of several cytokines were reported to be elevated in the peritoneal fluid of women with endometriosis. Because the peritoneal environment may be controlled by locally regulated factors, cytokines are believed to play a role in the development and progression of endometriosis and endometriosis-associated infertility. A possible pathogenic mechanism links cytokines with endometriosis. CONCLUSION(S) Cytokines, which are produced by many cell types including endometriotic tissues, play diverse roles in the pathogenesis of endometriosis and endometriosis-associated infertility. More studies about the specific role of these cells and soluble factors are needed to improve understanding of endometriosis and to develop novel therapies.
Collapse
Affiliation(s)
- T Harada
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
| | | | | |
Collapse
|
38
|
Akeshima R, Kigawa J, Takahashi M, Oishi T, Kanamori Y, Itamochi H, Shimada M, Kamazawa S, Sato S, Terakawa N. Telomerase activity and p53-dependent apoptosis in ovarian cancer cells. Br J Cancer 2001; 84:1551-5. [PMID: 11384107 PMCID: PMC2363666 DOI: 10.1054/bjoc.2001.1812] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
We conducted the present study to determine the relationship between p53-dependent apoptosis and telomerase activity in ovarian cancer cells. A human ovarian adenocarcinoma cell line, SK-OV-3 that had homozygous deletion of the p53 gene was used in this study. Wild-type p53 genes were transducted to SK-OV-3 cells with a recombinant adenovirus that contained a wild-type p53 gene (AxCAp53). IC(50)to cisplatin (CDDP) was 12.9 microM for SK-OV-3 cells and 9.2 microM for p53 gene-transducted SK-OV-3 cells. The apoptotic index for cells with p53 gene transduction was significantly higher than cells without transduction. Additionally, p53 gene transduction significantly enhanced CDDP-induced apoptosis. Bax protein in SK-OV-3 cells did not differ before and after exposure to CDDP. In SK-OV-3 cells with transduction of the p53 gene, the expression of p53 and Bax proteins increased after exposure to CDDP. Expression of Bcl-xL decreased after exposure to CDDP in SK-OV-3 cells with and without transduction. The telomerase activity in SK-OV-3 cells with the p53 gene was significantly lower compared with the cells without the p53 gene. CDDP exposure did not affect telomerase activity and human telomerase reverse transcriptase (hTERT) expression in both cell lines. We suggest that the p53 gene may relate to telomerase activity, but that p53-dependent apoptosis does not affect the activity.
Collapse
Affiliation(s)
- R Akeshima
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishimachi, Yonago, 6838504, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297:1137-43. [PMID: 11356939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023] Open
Abstract
To evaluate whether mutations in the human multidrug resistance (MDR)-1 gene correlate with placental P-glycoprotein (PGP) expression, we sequenced the MDR-1 cDNA and measured PGP expression by Western blotting in 100 placentas obtained from Japanese women. Nine single nucleotide polymorphisms (SNPs) were observed with an allelic frequency of 0.005 to 0.420. Of these SNPs, G2677A (allelic frequency = 0.18) and G2677T (0.39) in exon 21 were associated with an amino acid conversion from Ala to Thr and to Ser, respectively. Sixty-one of 65 samples (93.8%), which had a C3435T allele, also had a mutant G2677(A,T) allele, suggesting an association between the two SNPs. Correlations of mutations with expression levels were observed; individuals having the G2677(A,T) and/or T-129C (p < 0.05) allele had less placental PGP. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)-based genotyping tests were developed for the detection of these SNPs. The PCR, in which genomic DNAs obtained from healthy subjects (n = 48) are used as samples, was successful. The frequency of mutations in placental cDNA was identical with that in genomic DNA. When genotype results were compared between Caucasians and Japanese, ethnic differences in the frequency of polymorphism in the MDR-1 gene were suspected. Although it remains to be determined whether these SNPs influence the pharmacokinetic and dynamic properties of clinically useful drugs that are substrates of PGP, the polymorphism of the MDR-1 gene presented here may provide useful information in in vivo study of these issues.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis
- ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis
- ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
- Alleles
- Amino Acid Substitution
- Asian People/genetics
- Blotting, Western
- DNA Mutational Analysis
- Female
- Gene Frequency
- Genes, MDR/genetics
- Genetic Linkage
- Genotype
- Humans
- Immunohistochemistry
- Japan
- Placenta/cytology
- Placenta/metabolism
- Polymerase Chain Reaction
- Polymorphism, Restriction Fragment Length
- Polymorphism, Single Nucleotide
- White People/genetics
Collapse
Affiliation(s)
- M Tanabe
- Department of Clinical Pharmacokinetics, Division of Pharmaceutical Sciences, Graduate School, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Ito M, Harada T, Tanikawa M, Fujii A, Shiota G, Terakawa N. Hepatocyte growth factor and stem cell factor involvement in paracrine interplays of theca and granulosa cells in the human ovary. Fertil Steril 2001; 75:973-9. [PMID: 11334911 DOI: 10.1016/s0015-0282(01)01747-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To examine gene expression of hepatocyte growth factor (HGF), the receptor for HGF, c-met, and the receptor for stem cell factor (SCF), c-kit, in the human ovary and to investigate the effects of HGF and SCF on the proliferation and function of granulosa and theca cells. DESIGN Prospective study. SETTING University hospital. PATIENT(S) Six premenopausal women. INTERVENTION(S) Follicular fluid and granulosa cells were collected during IVF cycles. Ovarian tissues were obtained from women who underwent surgery. MAIN OUTCOME MEASURE(S) Gene expression of HGF, c-met, and c-kit in the human ovary was determined. RESULT(S) Reverse-transcription polymerase chain reaction showed the presence of HGF and c-kit mRNA in the theca and stroma cells of the ovary, whereas c-met mRNA was observed in the granulosa, theca, and stroma cells. HGF increased the expression of SCF gene in granulosa cells, and SCF reciprocally increased the expression of HGF gene in theca cells. SCF stimulated the proliferation of theca cells. HGF stimulated progesterone production in granulosa cells. CONCLUSION(S) A positive feedback loop between theca cells and granulosa cells was identified that is mediated by HGF and SCF. HGF and SCF modulate the interplay between theca and granulosa cells by promoting cell proliferation and steroid hormone production.
Collapse
Affiliation(s)
- M Ito
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
| | | | | | | | | | | |
Collapse
|
41
|
Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S, Sato S, Akeshima R, Terakawa N. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001; 7:892-5. [PMID: 11309338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
The tumor suppressor PTEN acts as a lipid phosphatase, regulates the phosphatidylinositol 3-kinase (PI3K)/Akt-signaling pathway, and modulates cell cycle progression and cell survival. Somatic mutations of PTEN have been reported in a variety of cancers, especially in endometrial carcinoma. To clarify whether and how PTEN and the PI3K/Akt pathway relates to endometrial carcinoma, we examined the expression of those pathway-related proteins in patients with endometrial carcinoma. Of 103 endometrial carcinomas, 37 (36%) showed negative immunohistochemical staining of PTEN. Western blotting revealed that the expression of PTEN in PTEN-negative cases was significantly lower compared with that in positive cases. In contrast, phospho-Akt level in negative cases was significantly higher. We found a significant inverse correlation between PTEN and phospho-Akt (r = -0.796). The expression of phospho-Bad was greater in negative cases, suggesting that Bad might be a target for AKT: The present study demonstrates the phosphorylation of Akt accompanied by the loss of PTEN in clinical specimens of endometrial carcinomas.
Collapse
Affiliation(s)
- Y Kanamori
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago 683-8504, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Ohata Y, Harada T, Ito M, Yoshida S, Iwabe T, Terakawa N. Coasting may reduce the severity of the ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome. Gynecol Obstet Invest 2001; 50:186-8. [PMID: 11014952 DOI: 10.1159/000010307] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The aim of our study was to determine the efficacy of postponing administration of human chorionic gonadotropin while continuing daily gonadotropin-releasing hormone agonist therapy ('coasting') to prevent the occurrence of severe ovarian hyperstimulation syndrome (OHSS) for patients with polycystic ovary (PCO) syndrome. Five patients with PCO who had been hospitalized due to severe OHSS in previous in vitro fertilization and embryo transfer or intrauterine insemination cycles at the Tottori University Hospital were included in the study. The rates of mature oocytes and fertilization were comparable between the cycles. A singleton pregnancy was achieved in a patient during the coasting cycle, and none of the women developed severe OHSS in coasting cycles. The results suggest that coasting may be an alternative method for reducing the severity of OHSS in patients with PCO.
Collapse
Affiliation(s)
- Y Ohata
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
| | | | | | | | | | | |
Collapse
|
43
|
Affiliation(s)
- N Terakawa
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
| |
Collapse
|
44
|
Ito T, Katagiri C, Ikeno S, Takahashi H, Nagata N, Terakawa N. Phenobarbital following phototherapy for Crigler-Najjar syndrome type II with good fetal outcome: a case report. J Obstet Gynaecol Res 2001; 27:33-5. [PMID: 11330728 DOI: 10.1111/j.1447-0756.2001.tb01212.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In the presence of severe hyperbilirubinemia in Crigler-Najjar syndrome Type II, a fetus is at risk for kernicterus. A 34-year-old woman, gravida 4, para 1, with Crigler-Najjar syndrome Type II was treated with phenobarbital administration following phototherapy during each of 2 pregnancies. Both infants were healthy and developed normally.
Collapse
Affiliation(s)
- T Ito
- Department of Obstetrics and Gynecology, Hakuai Hospital, Yonago, Japan
| | | | | | | | | | | |
Collapse
|
45
|
Sawa R, Hayashi Z, Tanaka T, Onda T, Hoshi K, Fukada Y, Takai Y, Taketani Y, Kubo T, Hamada H, Yoshida K, Nakamura Y, Okai T, Sakai M, Kaneoka T, Makino Y, Aono T, Maeda K, Honda R, Okamura H, Sago H, Kitagawa M, Minoura S, Inaba J, Terakawa N, Nagata N, Shimomura K, Sapeta MJ, Estabrooks LL. Rapid detection of chromosome aneuploidies by prenatal interphase FISH (fluorescence in situ hybridization) and its clinical utility in Japan. J Obstet Gynaecol Res 2001; 27:41-7. [PMID: 11330730 DOI: 10.1111/j.1447-0756.2001.tb01214.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE The purpose of this study was to assess the accuracy, informative rate, detection rate, and clinical utility of prenatal interphase fluorescence in situ hybridization (FISH) analysis of amniotic fluid samples from Japanese women. METHODS Amniotic fluid specimens from 2,639 Japanese women were received for prenatal interphase FISH and chromosome analysis. A questionnaire was designed to evaluate FISH clinical utility by collaboration sites. RESULTS Based on 2,319 tested samples, the accuracy (100%), informative (94%), and detection (87.6%) rates were all high. The accuracy (100%), informative (90.2%), and detection (90.0%) rates were also remarkable in third-trimester pregnancies. We perceive significant advantages from this test regarding medical management and patient satisfaction. CONCLUSIONS This novel report shows that in Japan prenatal interphase FISH testing is highly informative and accurate, not only in second-trimester pregnancies but also in third-trimester pregnancies. This test provides advantages to both physicians and patients, provided that its capabilities and limitations are understood.
Collapse
Affiliation(s)
- R Sawa
- Department of Obstetrics and Gynecology, Nippon Medical School, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Terakawa N. [Epidemiology of endometriosis]. Nihon Rinsho 2001; 59 Suppl 1:8-12. [PMID: 11235183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Affiliation(s)
- N Terakawa
- Department of Obstetrics and Gynecology, Tottori University School of Medicine
| |
Collapse
|
47
|
Kamazawa S, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Takahashi M, Sato S, Akeshima R, Terakawa N. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. Oncology 2000; 59:329-35. [PMID: 11096346 DOI: 10.1159/000012191] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVE The aim of this study was to evaluate the combination effect of paclitaxel (PTX) and cisplatin (CDDP) and to determine the mechanisms of interaction between these agents. METHODS AND RESULTS We used human ovarian adenocarcinoma cell lines, namely a parent cell line (KF), a CDDP-resistant cell line (KFr) and a PTX-resistant cell line (KFTx).The combination effect of PTX and CDDP was synergistic on KF and KFTx and additive on KFr. The incidence of anaphase or telophase, evaluated by immunofluorescence microscopy, decreased with PTX and significantly decreased with PTX and CDDP in KF and KFTx. The concentration of PTX, which was measured by high-performance liquid chromatography, was higher in KF and KFTx cells treated with a combination of PTX and CDDP than those treated with PTX alone. Multidrug resistance gene mRNA appeared in KFTx and its expression decreased after exposure to PTX and CDDP. After exposure to CDDP, the expression of multidrug resistance-associated protein (MRP) and the concentration of glutathione increased in KF, but not in KFr or KFTx. MRP expression slightly increased in KF and KFTx after exposure to PTX. In contrast, its expression decreased in KFr. CONCLUSION The present study suggests that CDDP enhances PTX accumulation and that the interaction of these agents is synergistic in CDDP-sensitive cells.
Collapse
Affiliation(s)
- S Kamazawa
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Shimada M, Kigawa J, Kanamori Y, Itamochi H, Takahashi M, Kamazawa S, Sato S, Terakawa N. Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts. Eur J Cancer 2000; 36:1869-75. [PMID: 10974636 DOI: 10.1016/s0959-8049(00)00161-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
To clarify the effect of a combination treatment consisting of a recombinant adenovirus carrying a wild-type TP53 gene (AxCATP53) and cisplatin (CDDP), we examined p53-dependent apoptosis in ovarian cancer xenografts with and without the wild-type TP53 gene. Severe combined immunodeficiency (SCID) mice were implanted with ovarian cancer cell lines consisting of SK-OV-3 cells without the TP53 gene and KF cells with the TP53 gene. In SK-OV-3 and KF tumours, the inhibitory effect of the combination treatment on tumour growth was significant, compared with a single treatment with CDDP alone or AxCATP53 alone. The apoptotic index increased significantly after combination treatment in the SK-OV-3 tumours. The expression of Bax protein in SK-OV-3 tumours was weak, but strengthened after TP53 gene transfection. In contrast, AxCATP53 transfection did not affect CDDP-induced apoptosis in the KF tumours. Therefore, combination treatment of AxCATP53 and CDDP may be a new strategy for treating ovarian cancer with or without the TP53 gene.
Collapse
Affiliation(s)
- M Shimada
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishimachi, 6838504, Yonago, Japan
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Takahashi M, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Kamazawa S, Sato S, Akeshima R, Terakawa N. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 2000; 36:1863-8. [PMID: 10974635 DOI: 10.1016/s0959-8049(00)00183-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
We conducted this study to determine whether the sensitivity of ovarian cancer cells to paclitaxel (PTX) relates to cells undergoing p53-dependent apoptosis. Human ovarian adenocarcinoma cell lines (SK-OV-3, KF and KP cells) were used in this study. In SK-OV-3 and KP cells, which have a homozygous deletion of the TP53 gene, wild-type TP53 gene-transduction markedly enhanced the sensitivity to cisplatin (CDDP), but did not enhance the sensitivity to PTX. In all cells, the apoptotic index was increased by CDDP or PTX. After exposure to CDDP, p53 and Bax protein expression increased and Bcl-xL expression decreased in the KF cells and TP53 gene-transducted SK-OV-3 cells. However, these proteins did not change in KP cells. Therefore, the role of p53 in CDDP-induced apoptosis depends upon the cell type. In contrast, TP53 gene status did not correlate with PTX-induced cytotoxicity in any of the cell lines with differing apoptotic pathways. In conclusion, the sensitivity to PTX may not be related to p53-dependent apoptosis in ovarian cancer cells.
Collapse
Affiliation(s)
- M Takahashi
- Department of Obstetrics and Gynecology, Tottori University, School of Medicine, 36-1 Nishimachi, 683-8507, Yonago, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Harada T, Enatsu A, Mitsunari M, Nagano Y, Ito M, Tsudo T, Taniguchi F, Iwabe T, Tanikawa M, Terakawa N. Role of cytokines in progression of endometriosis. Gynecol Obstet Invest 2000; 47 Suppl 1:34-9; discussion 39-40. [PMID: 10087426 DOI: 10.1159/000052857] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Peritoneal fluid in women with endometriosis contains an increased number of activated macrophages that secrete a variety of cytokines, including interleukin (IL)-6, IL-8, vascular endothelial growth factor, and tumor necrosis factor-alpha (TNF-alpha). Cytokines may be involved in the control of implantation and the growth of endometrial cells outside the uterus. In addition, several cytokines have been implicated in or directly associated with angiogenic activity in endometriosis. There could be a relationship between the levels of cytokines in the peritoneal fluid of patients with endometriosis and the status of the lesions in such patients. Peritoneal endometriosis can be classified as having red, black, or white lesions. Red lesions are known to be an active form of early endometriosis, because vascularization and mitotic activity are shown to be most prominent in these lesions. We found that the peritoneal fluid levels of TNF-alpha and IL-8 were significantly higher in patients with endometriosis, and correlated with the size and number of active lesions. In addition, TNF-alpha and IL-8 stimulated the growth of ectopic endometrial stromal cells. These cytokines with angiogenic activity may therefore have significant roles in the pathogenesis of endometriosis.
Collapse
Affiliation(s)
- T Harada
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|